Document is current
Any future updates will be listed below
-
Authors
Soehnlein, Oliver https://orcid.org/0000-0002-7854-0694
Libby, Peter https://orcid.org/0000-0002-1502-502X
- License Information
-
More Information
Article History
Accepted: 29 March 2021
First Online: 11 May 2021
Competing interests
: O.S. holds two patents on targeting histones in inflammation and one on disrupting CCL5-HNP1 heteromers, and also receives funding from Novo Nordisk to study chronopharmacological treatment strategies in cardiovascular disease. P.L. is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis and XBiotech, Inc. P.L.’s laboratory has received research funding in the past 2 years from Novartis. P.L. is on the Board of Directors of XBiotech, Inc. P.L. has a financial interest in Xbiotech, a company developing therapeutic human antibodies. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.
